1
|
Maybee DV, Cromwell CR, Hubbard BP, Ali MAM. MMP-2 regulates Src activation via repression of the CHK/MATK tumor suppressor in osteosarcoma. Cancer Rep (Hoboken) 2023; 7:e1946. [PMID: 38064181 PMCID: PMC10849928 DOI: 10.1002/cnr2.1946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2023] [Revised: 08/22/2023] [Accepted: 09/14/2023] [Indexed: 02/12/2024] Open
Abstract
BACKGROUND Doxorubicin, a first-line anticancer drug for osteosarcoma treatment, has been the subject of recent research exploring the mechanisms behind its chemoresistance and its ability to enhance cell migration at sublethal concentrations. Matrix metalloproteinase-2 (MMP-2), a type IV collagenase and zinc-dependent endopeptidase, is well-known for degrading the extracellular matrix and promoting cancer metastasis. Our previous work demonstrated that nuclear MMP-2 regulates ribosomal RNA transcription via histone clipping, thereby controlling gene expression. Additionally, MMP-2 activity is regulated by the non-receptor tyrosine kinase and oncogene, Src, which plays a crucial role in cell adhesion, invasion, and metastasis. Src kinase is primarily regulated by two endogenous inhibitors: C-terminal Src kinase (Csk) and Csk homologous kinase (CHK/MATK). AIM In this study, we reveal that the MMP-2 gene acts as an upstream regulator of Src kinase activity by suppressing its endogenous inhibitor, CHK/MATK, in osteosarcoma cells. METHODS AND RESULTS We show that enhanced osteosarcoma cell migration which is induced by sublethal concentrations of doxorubicin can be overcome by inactivating the MMP-2 gene or overexpressing CHK/MATK. Our findings highlight the MMP-2 gene as a promising additional target for combating cancer cell migration and metastasis. This is due to its role in suppressing on the gene and protein expression of the tumor suppressor CHK/MATK in osteosarcoma. CONCLUSION By targeting the MMP-2 gene, we can potentially enhance the effectiveness of doxorubicin treatment and reduce chemoresistance in osteosarcoma.
Collapse
Affiliation(s)
- Deanna V. Maybee
- Department of Pharmaceutical SciencesSUNY Binghamton University School of Pharmacy and Pharmaceutical SciencesBinghamtonNew YorkUSA
| | | | - Basil P. Hubbard
- Department of Pharmacology and ToxicologyUniversity of TorontoTorontoOntarioCanada
| | - Mohammad A. M. Ali
- Department of Pharmaceutical SciencesSUNY Binghamton University School of Pharmacy and Pharmaceutical SciencesBinghamtonNew YorkUSA
| |
Collapse
|
2
|
Chen J, Farraj RA, Limonta D, Tabatabaei Dakhili SA, Kerek EM, Bhattacharya A, Reformat FM, Mabrouk OM, Brigant B, Pfeifer TA, McDermott MT, Ussher JR, Hobman TC, Glover JNM, Hubbard BP. Reversible and irreversible inhibitors of coronavirus Nsp15 endoribonuclease. J Biol Chem 2023; 299:105341. [PMID: 37832873 PMCID: PMC10656235 DOI: 10.1016/j.jbc.2023.105341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Revised: 10/04/2023] [Accepted: 10/07/2023] [Indexed: 10/15/2023] Open
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2, the causative agent of coronavirus disease 2019, has resulted in the largest pandemic in recent history. Current therapeutic strategies to mitigate this disease have focused on the development of vaccines and on drugs that inhibit the viral 3CL protease or RNA-dependent RNA polymerase enzymes. A less-explored and potentially complementary drug target is Nsp15, a uracil-specific RNA endonuclease that shields coronaviruses and other nidoviruses from mammalian innate immune defenses. Here, we perform a high-throughput screen of over 100,000 small molecules to identify Nsp15 inhibitors. We characterize the potency, mechanism, selectivity, and predicted binding mode of five lead compounds. We show that one of these, IPA-3, is an irreversible inhibitor that might act via covalent modification of Cys residues within Nsp15. Moreover, we demonstrate that three of these inhibitors (hexachlorophene, IPA-3, and CID5675221) block severe acute respiratory syndrome coronavirus 2 replication in cells at subtoxic doses. This study provides a pipeline for the identification of Nsp15 inhibitors and pinpoints lead compounds for further development against coronavirus disease 2019 and related coronavirus infections.
Collapse
Affiliation(s)
- Jerry Chen
- Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
| | - Rabih Abou Farraj
- Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada
| | - Daniel Limonta
- Department of Cell Biology, Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, California, USA; Gladstone Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, California, USA
| | | | - Evan M Kerek
- Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
| | - Ashim Bhattacharya
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada
| | - Filip M Reformat
- Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
| | - Ola M Mabrouk
- Department of Chemistry, University of Alberta, Edmonton, Alberta, Canada
| | - Benjamin Brigant
- Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
| | - Tom A Pfeifer
- High Throughput Biology Facility, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada
| | - Mark T McDermott
- Department of Chemistry, University of Alberta, Edmonton, Alberta, Canada
| | - John R Ussher
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
| | - Tom C Hobman
- Department of Cell Biology, Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada
| | - J N Mark Glover
- Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada
| | - Basil P Hubbard
- Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
| |
Collapse
|
3
|
Schmidt EN, Lamprinaki D, McCord KA, Joe M, Sojitra M, Waldow A, Nguyen J, Monyror J, Kitova EN, Mozaneh F, Guo XY, Jung J, Enterina JR, Daskhan GC, Han L, Krysler AR, Cromwell CR, Hubbard BP, West LJ, Kulka M, Sipione S, Klassen JS, Derda R, Lowary TL, Mahal LK, Riddell MR, Macauley MS. Siglec-6 mediates the uptake of extracellular vesicles through a noncanonical glycolipid binding pocket. Nat Commun 2023; 14:2327. [PMID: 37087495 PMCID: PMC10122656 DOI: 10.1038/s41467-023-38030-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Accepted: 04/12/2023] [Indexed: 04/24/2023] Open
Abstract
Immunomodulatory Siglecs are controlled by their glycoprotein and glycolipid ligands. Siglec-glycolipid interactions are often studied outside the context of a lipid bilayer, missing the complex behaviors of glycolipids in a membrane. Through optimizing a liposomal formulation to dissect Siglec-glycolipid interactions, it is shown that Siglec-6 can recognize glycolipids independent of its canonical binding pocket, suggesting that Siglec-6 possesses a secondary binding pocket tailored for recognizing glycolipids in a bilayer. A panel of synthetic neoglycolipids is used to probe the specificity of this glycolipid binding pocket on Siglec-6, leading to the development of a neoglycolipid with higher avidity for Siglec-6 compared to natural glycolipids. This neoglycolipid facilitates the delivery of liposomes to Siglec-6 on human mast cells, memory B-cells and placental syncytiotrophoblasts. A physiological relevance for glycolipid recognition by Siglec-6 is revealed for the binding and internalization of extracellular vesicles. These results demonstrate a unique and physiologically relevant ability of Siglec-6 to recognize glycolipids in a membrane.
Collapse
Affiliation(s)
- Edward N Schmidt
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | | | - Kelli A McCord
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | - Maju Joe
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | - Mirat Sojitra
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | - Ayk Waldow
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | - Jasmine Nguyen
- Department of Obstetrics & Gynaecology and Physiology University of Alberta, Edmonton, AB, Canada
| | - John Monyror
- Department of Pharmacology, University of Alberta, Edmonton, AB, Canada
- Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada
| | - Elena N Kitova
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | - Fahima Mozaneh
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | - Xue Yan Guo
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | - Jaesoo Jung
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | - Jhon R Enterina
- Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada
| | - Gour C Daskhan
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | - Ling Han
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | - Amanda R Krysler
- Department of Pharmacology, University of Alberta, Edmonton, AB, Canada
| | | | - Basil P Hubbard
- Department of Pharmacology, University of Alberta, Edmonton, AB, Canada
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
| | - Lori J West
- Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada
- Department of Pediatrics, University of Alberta, Edmonton, AB, Canada
- Department of Surgery, University of Alberta, Edmonton, AB, Canada
| | - Marianne Kulka
- Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada
- National Research Council, Edmonton, AB, Canada
| | - Simonetta Sipione
- Department of Pharmacology, University of Alberta, Edmonton, AB, Canada
- Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada
| | - John S Klassen
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | - Ratmir Derda
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | - Todd L Lowary
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
- Institute of Biological Chemistry, Academia Sinica, Nangang, Taipei, Taiwan
- Institute of Biochemical Sciences, National Taiwan University, Taipei, Taiwan
| | - Lara K Mahal
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | - Meghan R Riddell
- Department of Obstetrics & Gynaecology and Physiology University of Alberta, Edmonton, AB, Canada
| | - Matthew S Macauley
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada.
- Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada.
- Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada.
| |
Collapse
|
4
|
Park H, Osman EA, Cromwell CR, St Laurent CD, Liu Y, Kitova EN, Klassen JS, Hubbard BP, Macauley MS, Gibbs JM. CRISPR-Click Enables Dual-Gene Editing with Modular Synthetic sgRNAs. Bioconjug Chem 2022; 33:858-868. [PMID: 35436106 DOI: 10.1021/acs.bioconjchem.2c00106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Gene-editing systems such as CRISPR-Cas9 readily enable individual gene phenotypes to be studied through loss of function. However, in certain instances, gene compensation can obfuscate the results of these studies, necessitating the editing of multiple genes to properly identify biological pathways and protein function. Performing multiple genetic modifications in cells remains difficult due to the requirement for multiple rounds of gene editing. While fluorescently labeled guide RNAs (gRNAs) are routinely used in laboratories for targeting CRISPR-Cas9 to disrupt individual loci, technical limitations in single gRNA (sgRNA) synthesis hinder the expansion of this approach to multicolor cell sorting. Here, we describe a modular strategy for synthesizing sgRNAs where each target sequence is conjugated to a unique fluorescent label, which enables fluorescence-activated cell sorting (FACS) to isolate cells that incorporate the desired combination of gene-editing constructs. We demonstrate that three short strands of RNA functionalized with strategically placed 5'-azide and 3'-alkyne terminal deoxyribonucleotides can be assembled in a one-step, template-assisted, copper-catalyzed alkyne-azide cycloaddition to generate fully functional, fluorophore-modified sgRNAs. Using these synthetic sgRNAs in combination with FACS, we achieved selective cleavage of two targeted genes, either separately as a single-color experiment or in combination as a dual-color experiment. These data indicate that our strategy for generating double-clicked sgRNA allows for Cas9 activity in cells. By minimizing the size of each RNA fragment to 41 nucleotides or less, this strategy is well suited for custom, scalable synthesis of sgRNAs.
Collapse
Affiliation(s)
- Hansol Park
- Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada
| | - Eiman A Osman
- Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada
| | | | - Chris D St Laurent
- Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada
| | - Yuning Liu
- Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada
| | - Elena N Kitova
- Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada
| | - John S Klassen
- Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada
| | - Basil P Hubbard
- Department of Pharmacology, University of Alberta, Edmonton, Alberta T6G 2H7, Canada
| | - Matthew S Macauley
- Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada
- Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2R7, Canada
| | - Julianne M Gibbs
- Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada
| |
Collapse
|
5
|
Boukouris AE, Zhang Y, Saleme B, Kinnaird A, Zhao YY, Liu Y, Zervopoulos SD, Das SK, Mittal RD, Haromy A, Lorenzana-Carrillo MA, Krysler AR, Cromwell CR, Hubbard BP, Sutendra G, Michelakis ED. A reversible metabolic stress-sensitive regulation of CRMP2A orchestrates EMT/stemness and increases metastatic potential in cancer. Cell Rep 2022; 38:110511. [PMID: 35294884 DOI: 10.1016/j.celrep.2022.110511] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2021] [Revised: 11/09/2021] [Accepted: 02/17/2022] [Indexed: 12/31/2022] Open
Abstract
An epithelial-to-mesenchymal transition (EMT) phenotype with cancer stem cell-like properties is a critical feature of aggressive/metastatic tumors, but the mechanism(s) that promote it and its relation to metabolic stress remain unknown. Here we show that Collapsin Response Mediator Protein 2A (CRMP2A) is unexpectedly and reversibly induced in cancer cells in response to multiple metabolic stresses, including low glucose and hypoxia, and inhibits EMT/stemness. Loss of CRMP2A, when metabolic stress decreases (e.g., around blood vessels in vivo) or by gene deletion, induces extensive microtubule remodeling, increased glutamine utilization toward pyrimidine synthesis, and an EMT/stemness phenotype with increased migration, chemoresistance, tumor initiation capacity/growth, and metastatic potential. In a cohort of 27 prostate cancer patients with biopsies from primary tumors and distant metastases, CRMP2A expression decreases in the metastatic versus primary tumors. CRMP2A is an endogenous molecular brake on cancer EMT/stemness and its loss increases the aggressiveness and metastatic potential of tumors.
Collapse
Affiliation(s)
| | - Yongneng Zhang
- Department of Medicine, University of Alberta, Edmonton, AB, Canada
| | - Bruno Saleme
- Department of Medicine, University of Alberta, Edmonton, AB, Canada
| | - Adam Kinnaird
- Department of Surgery, University of Alberta, Edmonton, AB, Canada
| | - Yuan Yuan Zhao
- Department of Medicine, University of Alberta, Edmonton, AB, Canada
| | - Yongsheng Liu
- Department of Medicine, University of Alberta, Edmonton, AB, Canada
| | | | - Subhash K Das
- Department of Medicine, University of Alberta, Edmonton, AB, Canada
| | - Rohan D Mittal
- Department of Pathology, University of Alberta, Edmonton, AB, Canada
| | - Alois Haromy
- Department of Medicine, University of Alberta, Edmonton, AB, Canada
| | | | - Amanda R Krysler
- Department of Pharmacology, University of Alberta, Edmonton, AB, Canada
| | | | - Basil P Hubbard
- Department of Pharmacology, University of Alberta, Edmonton, AB, Canada
| | | | | |
Collapse
|
6
|
Tang X, Cromwell CR, Liu R, Godbout R, Hubbard BP, McMullen TP, Brindley DN. Lipid phosphate phosphatase-2 promotes tumor growth through increased c-Myc expression. Am J Cancer Res 2022; 12:5675-5690. [PMID: 35966578 PMCID: PMC9373824 DOI: 10.7150/thno.66230] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Accepted: 07/13/2022] [Indexed: 12/02/2022] Open
Abstract
LPP2 is one of three enzymes in the lipid phosphate phosphatase family (LPP1-3) that dephosphorylate extracellular and intracellular bioactive lipid phosphates and pyrophosphates. LPP2 increases cell growth and LPP2 expression is elevated in a variety of malignancies, implying that LPP2 is a pro-tumorigenic factor. Methods: LPP2 expression in human breast tumors and normal breast tissue was measured by qPCR. To understand the role of LPP2, we knocked out its expression in multiple cell lines using CRISPR/Cas9. Cell proliferation and migration were compared between wild type and LPP2 knockout cells. Cell cycle was measured by flow cytometry, and cell cycle proteins were determined by western blotting. Effects of LPP2 on tumor growth were investigated using syngeneic and xenograft mouse breast cancer models. Results: LPP2 mRNA levels were higher in ER/PR positive, ER/HER2 positive, and triple negative human breast tumors, relative to normal breast tissue. Higher levels of LPP2 in breast tumors, hepatocellular carcinoma, pancreatic adenocarcinoma, and melanomas were prognostic of poorer survival. LPP2 mRNA expression is also increased in Hs-578T, MDA-MB-231, MCF7 and MDA-MB-468 breast cancer cell lines, relative to non-malignant Hs-578Bst, MCF10A and MCF-12A cells. LPP2 knockout in breast cancer cells decreased cell growth by inhibiting G1/S transition, whereas, increasing LPP2 levels in Hs-578Bst and MCF10A cells promoted proliferation. The effects of LPP2 on cell cycle were associated with changes in cyclin A2, cyclin B1, and cell cycle inhibitors, p27 or p21. The level of c-Myc was downregulated by knocking out LPP2, and it was partly restored by re-expressing LPP2. The positive correlation between the expression of LPP2 and c-Myc exists in multiple cancer cell lines including breast, lung, upper aerodigestive tract and urinary tract cancer. LPP2 knockout in MDA-MB-231 or 4T1 cells suppressed tumor formation in mouse breast cancer models, and decreased the in vivo expression of Ki67 and c-Myc of the cancer cells. Conclusion: Targeting LPP2 could provide a new strategy for decreasing c-Myc expression and tumor growth.
Collapse
|
7
|
Ali MAM, Garcia-Vilas JA, Cromwell CR, Hubbard BP, Hendzel MJ, Schulz R. Matrix metalloproteinase-2 mediates ribosomal RNA transcription by cleaving nucleolar histones. FEBS J 2021; 288:6736-6751. [PMID: 34101354 DOI: 10.1111/febs.16061] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Revised: 05/09/2021] [Accepted: 06/07/2021] [Indexed: 02/06/2023]
Abstract
Cell proliferation and survival require continuous ribosome biogenesis and protein synthesis. Genes encoding ribosomal RNA are physically located in a specialized substructure within the nucleus known as the nucleolus, which has a central role in the biogenesis of ribosomes. Matrix metalloproteinase-2 was previously detected in the nucleus, however, its role there is elusive. Herein we report that matrix metalloproteinase-2 resides within the nucleolus to regulate ribosomal RNA transcription. Matrix metalloproteinase-2 is enriched at the promoter region of ribosomal RNA gene repeats, and its inhibition downregulates preribosomal RNA transcription. The N-terminal tail of histone H3 is clipped by matrix metalloproteinase-2 in the nucleolus, which is associated with increased ribosomal RNA transcription. Knocking down/out matrix metalloproteinase-2, or inhibiting its activity, prevents histone H3 cleavage and reduces both ribosomal RNA transcription and cell proliferation. In addition to the known extracellular roles of matrix metalloproteinase-2 in tumor growth, our data reveal an epigenetic mechanism whereby intranucleolar matrix metalloproteinase-2 regulates cell proliferation through histone clipping and facilitation of ribosomal RNA transcription.
Collapse
Affiliation(s)
- Mohammad A M Ali
- Department of Pediatrics, Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, AB, Canada.,Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York, Binghamton, NY, USA
| | - Javier A Garcia-Vilas
- Department of Pediatrics, Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, AB, Canada.,Department of Pharmacology, Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, AB, Canada
| | - Christopher R Cromwell
- Department of Pharmacology, Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, AB, Canada
| | - Basil P Hubbard
- Department of Pharmacology, Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, AB, Canada
| | - Michael J Hendzel
- Department of Oncology, Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, AB, Canada
| | - Richard Schulz
- Department of Pediatrics, Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, AB, Canada.,Department of Pharmacology, Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, AB, Canada
| |
Collapse
|
8
|
Bhullar KS, Son M, Kerek E, Cromwell CR, Wingert BM, Wu K, Jovel J, Camacho CJ, Hubbard BP, Wu J. Tripeptide IRW Upregulates NAMPT Protein Levels in Cells and Obese C57BL/6J Mice. J Agric Food Chem 2021; 69:1555-1566. [PMID: 33522796 DOI: 10.1021/acs.jafc.0c07831] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Nicotinamide adenine dinucleotide (NAD+) plays a vital role in cellular processes that govern human health and disease. Nicotinamide phosphoribosyltransferase (NAMPT) is a rate-limiting enzyme in NAD+ biosynthesis. Thus, boosting NAD+ level via an increase in NAMPT levels is an attractive approach for countering the effects of aging and metabolic disease. This study aimed to establish IRW (Ile-Arg-Trp), a small tripeptide derived from ovotransferrin, as a booster of NAMPT levels. Treatment of muscle (L6) cells with IRW increased intracellular NAMPT protein levels (2.2-fold, p < 0.05) and boosted NAD+ (p < 0.01). Both immunoprecipitation and recombinant NAMPT assays indicated the possible NAMPT-activating ability of IRW (p < 0.01). Similarly, IRW increased NAMPT mRNA and protein levels in the liver (2.6-fold, p < 0.01) and muscle tissues (2.3-fold, p < 0.05) of C57BL/6J mice fed with a high-fat diet (HFD). A significantly increased level of circulating NAD+ was also observed following IRW treatment (4.7 fold, p < 0.0001). Dosing of Drosophila melanogaster with IRW elevated both D-NAAM (fly NAMPT) and NAD+ in vivo (p < 0.05). However, IRW treatment did not boost NAMPT levels in SIRT1 KO cells, indicating a possible SIRT1 dependency for the pharmacological effect. Overall, these data indicate that IRW is a novel small peptide booster of the NAMPT pool.
Collapse
Affiliation(s)
- Khushwant S Bhullar
- Department of Agricultural, Food, and Nutritional Science, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
- Department of Pharmacology, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
- Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - Myoungjin Son
- Department of Agricultural, Food, and Nutritional Science, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - Evan Kerek
- Department of Pharmacology, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | | | - Bentley M Wingert
- Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States
| | - Kaiyu Wu
- Department of Agricultural, Food, and Nutritional Science, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - Juan Jovel
- Office of Research, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - Carlos J Camacho
- Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States
| | - Basil P Hubbard
- Department of Pharmacology, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - Jianping Wu
- Department of Agricultural, Food, and Nutritional Science, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| |
Collapse
|
9
|
Abstract
In addition to advancing the development of gene-editing therapeutics, CRISPR/Cas9 is transforming how functional genetic studies are carried out in the lab. By increasing the ease with which genetic information can be inserted, deleted, or edited in cell and organism models, it facilitates genotype-phenotype analysis. Moreover, CRISPR/Cas9 has revolutionized the speed at which new genes underlying a particular phenotype can be identified through its application in genomic screens. Arrayed high-throughput and pooled lentiviral-based CRISPR/Cas9 screens have now been used in a wide variety of contexts, including the identification of essential genes, genes involved in cancer metastasis and tumor growth, and even genes involved in viral response. This technology has also been successfully used to identify drug targets and drug resistance mechanisms. Here, we provide a detailed protocol for performing a genome-wide pooled lentiviral CRISPR/Cas9 knockout screen to identify genetic modulators of a small-molecule drug. While we exemplify how to identify genes involved in resistance to a cytotoxic histone deacetylase inhibitor, Trichostatin A (TSA), the workflow we present can easily be adapted to different types of selections and other types of exogenous ligands or drugs.
Collapse
Affiliation(s)
- Evan M Kerek
- Department of Pharmacology, University of Alberta, Edmonton, AB, Canada
| | | | - Basil P Hubbard
- Department of Pharmacology, University of Alberta, Edmonton, AB, Canada.
| |
Collapse
|
10
|
Abstract
The CRISPR/Cas9 system has transformed how gene knockout and knock-in studies are performed in the lab, and it is poised to revolutionize medicine. However, one of the present limitations of this technology is its imperfect specificity. While CRISPR/Cas9 can be programmed to cut a specific DNA target sequence with relative precision, off-target sequence cleavage can occur in large genomes. Importantly, several techniques have recently been developed to measure CRISPR/Cas9 on- and off-target DNA cleavage in cells. Here, we present detailed protocols for evaluating the specificity of CRISPR/Cas9 and related systems in cells using both targeted-approaches, in which off-target sites are known a priori, and unbiased approaches which are able to identify off-target cleavage events throughout an entire genome. Together, these techniques can be used to assess the reliability of experimental models generated using CRISPR/Cas9 as well as the safety of therapeutics employing this technology.
Collapse
Affiliation(s)
| | - Juan Jovel
- The Applied Genomics Core, Office of Research, University of Alberta, Edmonton, AB, Canada
| | - Basil P Hubbard
- Department of Pharmacology, University of Alberta, Edmonton, AB, Canada.
| |
Collapse
|
11
|
Abstract
CRISPR/Cas9 has revolutionized the ability to edit cellular DNA and is poised to transform the treatment of genetic diseases. One of the major concerns regarding its therapeutic use is the potential for off-target DNA cleavage, which could have detrimental consequences in vivo. To circumvent this, a number of strategies have been employed to develop next-generation CRISPR/Cas9 systems with improved specificity. These include the development of new protein variants of Cas9, as well as chemically modified guide RNA molecules. Here, we provide detailed protocols for two in vitro methods that enable the specificity of first- and next-generation CRISPR/Cas9 systems to be compared, and we demonstrate their applicability to evaluating chemically modified guide RNAs. One of these assays allows the specificity of different guide RNA/Cas9 complexes to be compared on a set of known off-target DNA sequences, while the second provides a broad specificity profile based on cleavage of a massive library of potential off-target DNA sequences. Collectively, these assays may be used to evaluate the specificity of different CRISPR/Cas9 systems on any DNA target sequence in a time- and cost-effective manner.
Collapse
Affiliation(s)
| | - Basil P Hubbard
- Department of Pharmacology, University of Alberta, Edmonton, AB, Canada.
| |
Collapse
|
12
|
Kerek EM, Yoon KH, Luo SY, Chen J, Valencia R, Julien O, Waskiewicz AJ, Hubbard BP. A conserved acetylation switch enables pharmacological control of tubby-like protein stability. J Biol Chem 2020; 296:100073. [PMID: 33187986 PMCID: PMC7948452 DOI: 10.1074/jbc.ra120.015839] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2020] [Revised: 10/30/2020] [Accepted: 11/13/2020] [Indexed: 12/29/2022] Open
Abstract
Tubby-like proteins (TULPs) are characterized by a conserved C-terminal domain that binds phosphoinositides. Collectively, mammalian TULP1-4 proteins play essential roles in intracellular transport, cell differentiation, signaling, and motility. Yet, little is known about how the function of these proteins is regulated in cells. Here, we present the protein–protein interaction network of TULP3, a protein that is responsible for the trafficking of G-protein-coupled receptors to cilia and whose aberrant expression is associated with severe developmental disorders and polycystic kidney disease. We identify several protein interaction nodes linked to TULP3 that include enzymes involved in acetylation and ubiquitination. We show that acetylation of two key lysine residues on TULP3 by p300 increases TULP3 protein abundance and that deacetylation of these sites by HDAC1 decreases protein levels. Furthermore, we show that one of these sites is ubiquitinated in the absence of acetylation and that acetylation inversely correlates with ubiquitination of TULP3. This mechanism is evidently conserved across species and is active in zebrafish during development. Finally, we identify this same regulatory module in TULP1, TULP2, and TULP4 and demonstrate that the stability of these proteins is similarly modulated by an acetylation switch. This study unveils a signaling pathway that links nuclear enzymes to ciliary membrane receptors via TULP3, describes a dynamic mechanism for the regulation of all tubby-like proteins, and explores how to exploit it pharmacologically using drugs.
Collapse
Affiliation(s)
- Evan M Kerek
- Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
| | - Kevin H Yoon
- Department of Biological Sciences, University of Alberta, Edmonton, Alberta, Canada
| | - Shu Y Luo
- Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada
| | - Jerry Chen
- Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
| | - Robert Valencia
- Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada
| | - Olivier Julien
- Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada
| | - Andrew J Waskiewicz
- Department of Biological Sciences, University of Alberta, Edmonton, Alberta, Canada
| | - Basil P Hubbard
- Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada.
| |
Collapse
|
13
|
Abstract
In this issue of Cell Chemical Biology, Erdogan et al. (2020) describe a new CRISPR/Cas9-based strategy for performing directed evolution of mammalian proteins in situ. Using this technique to select functional mRuby3 variants within lysosomes, they identify mCRISPRed, a fluorescent protein that displays robust stability and activity at low pH.
Collapse
Affiliation(s)
- Evan M Kerek
- Department of Pharmacology, University of Alberta, Edmonton, AB T6G 2R7, Canada
| | | | - Basil P Hubbard
- Department of Pharmacology, University of Alberta, Edmonton, AB T6G 2R7, Canada.
| |
Collapse
|
14
|
Salla M, Pandya V, Bhullar KS, Kerek E, Wong YF, Losch R, Ou J, Aldawsari FS, Velazquez-Martinez C, Thiesen A, Dyck JRB, Hubbard BP, Baksh S. Resveratrol and Resveratrol-Aspirin Hybrid Compounds as Potent Intestinal Anti-Inflammatory and Anti-Tumor Drugs. Molecules 2020; 25:molecules25173849. [PMID: 32847114 PMCID: PMC7503224 DOI: 10.3390/molecules25173849] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Revised: 08/04/2020] [Accepted: 08/11/2020] [Indexed: 02/07/2023] Open
Abstract
Resveratrol (3,4,5-Trihydroxy-trans-stilbene) is a naturally occurring polyphenol that exhibits beneficial pleiotropic health effects. It is one of the most promising natural molecules in the prevention and treatment of chronic diseases and autoimmune disorders. One of the key limitations in the clinical use of resveratrol is its extensive metabolic processing to its glucuronides and sulfates. It has been estimated that around 75% of this polyphenol is excreted via feces and urine. To possibly alleviate the extensive metabolic processing and improve bioavailability, we have added segments of acetylsalicylic acid to resveratrol in an attempt to maintain the functional properties of both. We initially characterized resveratrol-aspirin derivatives as products that can inhibit cytochrome P450 Family 1 Subfamily A Member 1 (CYP1A1) activity, DNA methyltransferase (DNMT) activity, and cyclooxygenase (COX) activity. In this study, we provide a detailed analysis of how resveratrol and its aspirin derivatives can inhibit nuclear factor kappa B (NFκB) activation, cytokine production, the growth rate of cancer cells, and in vivo alleviate intestinal inflammation and tumor growth. We identified resveratrol derivatives C3 and C11 as closely preserving resveratrol bioactivities of growth inhibition of cancer cells, inhibition of NFκB activation, activation of sirtuin, and 5’ adenosine monophosphate-activated protein kinase (AMPK) activity. We speculate that the aspirin derivatives of resveratrol would be more metabolically stable, resulting in increased efficacy for treating immune disorders and as an anti-cancer agent.
Collapse
Affiliation(s)
- Mohamed Salla
- Department of Biochemistry, Faculty of Medicine and Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada; (M.S.); (V.P.); (R.L.); (J.O.)
| | - Vrajesh Pandya
- Department of Biochemistry, Faculty of Medicine and Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada; (M.S.); (V.P.); (R.L.); (J.O.)
| | - Khushwant S. Bhullar
- Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada; (K.S.B.); (E.K.); (J.R.B.D.); (B.P.H.)
| | - Evan Kerek
- Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada; (K.S.B.); (E.K.); (J.R.B.D.); (B.P.H.)
| | - Yoke Fuan Wong
- Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada;
| | - Robyn Losch
- Department of Biochemistry, Faculty of Medicine and Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada; (M.S.); (V.P.); (R.L.); (J.O.)
| | - Joe Ou
- Department of Biochemistry, Faculty of Medicine and Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada; (M.S.); (V.P.); (R.L.); (J.O.)
| | - Fahad S. Aldawsari
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada or (F.S.A.); (C.V.-M.)
- Saudi Food and Drug Authority Laboratories, 3292 Northern Ring Road, Riyadh 13312, Saudi Arabia
| | - Carlos Velazquez-Martinez
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada or (F.S.A.); (C.V.-M.)
| | - Aducio Thiesen
- Department of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada;
| | - Jason R. B. Dyck
- Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada; (K.S.B.); (E.K.); (J.R.B.D.); (B.P.H.)
- Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada;
| | - Basil P. Hubbard
- Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada; (K.S.B.); (E.K.); (J.R.B.D.); (B.P.H.)
| | - Shairaz Baksh
- Department of Biochemistry, Faculty of Medicine and Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada; (M.S.); (V.P.); (R.L.); (J.O.)
- Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada;
- Departments of Oncology, Faculty of Medicine and Dentistry, University of Alberta, 113 Street 87 Avenue, Edmonton, AB T6G 2E1, Canada
- Member, Cancer Research Institute of Northern Alberta and Women and Children’s Health Research Institute, Edmonton, AB T6G 2E1, Canada
- BioImmuno Designs, Inc., 4560 TEC Centre, 10230 Jasper Avenue, Edmonton, AB T5J 4P6, Canada
- Correspondence: ; Tel.: +1-780-239-0518
| |
Collapse
|
15
|
Shang N, Bhullar KS, Hubbard BP, Wu J. Tripeptide IRW initiates differentiation in osteoblasts via the RUNX2 pathway. Biochim Biophys Acta Gen Subj 2019; 1863:1138-1146. [DOI: 10.1016/j.bbagen.2019.04.007] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2018] [Revised: 04/08/2019] [Accepted: 04/09/2019] [Indexed: 12/14/2022]
|
16
|
Cromwell CR, Sung K, Park J, Krysler AR, Jovel J, Kim SK, Hubbard BP. Incorporation of bridged nucleic acids into CRISPR RNAs improves Cas9 endonuclease specificity. Nat Commun 2018; 9:1448. [PMID: 29654299 PMCID: PMC5899152 DOI: 10.1038/s41467-018-03927-0] [Citation(s) in RCA: 118] [Impact Index Per Article: 19.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2017] [Accepted: 03/22/2018] [Indexed: 12/26/2022] Open
Abstract
Off-target DNA cleavage is a paramount concern when applying CRISPR-Cas9 gene-editing technology to functional genetics and human therapeutic applications. Here, we show that incorporation of next-generation bridged nucleic acids (2',4'-BNANC[N-Me]) as well as locked nucleic acids (LNA) at specific locations in CRISPR-RNAs (crRNAs) broadly reduces off-target DNA cleavage by Cas9 in vitro and in cells by several orders of magnitude. Using single-molecule FRET experiments we show that BNANC incorporation slows Cas9 kinetics and improves specificity by inducing a highly dynamic crRNA-DNA duplex for off-target sequences, which shortens dwell time in the cleavage-competent, "zipped" conformation. In addition to describing a robust technique for improving the precision of CRISPR/Cas9-based gene editing, this study illuminates an application of synthetic nucleic acids.
Collapse
Affiliation(s)
| | - Keewon Sung
- Department of Chemistry, Seoul National University, Seoul, 08826, Republic of Korea
| | - Jinho Park
- Department of Chemistry, Seoul National University, Seoul, 08826, Republic of Korea
| | - Amanda R Krysler
- Department of Pharmacology, University of Alberta, Edmonton, AB, T6G 2R7, Canada
| | - Juan Jovel
- The Applied Genomics Core, Office of Research, University of Alberta, Edmonton, AB, T6G 2E1, Canada
| | - Seong Keun Kim
- Department of Chemistry, Seoul National University, Seoul, 08826, Republic of Korea
| | - Basil P Hubbard
- Department of Pharmacology, University of Alberta, Edmonton, AB, T6G 2R7, Canada.
| |
Collapse
|
17
|
Salla M, Aguayo-Ortiz R, Danmaliki GI, Zare A, Said A, Moore J, Pandya V, Manaloor R, Fong S, Blankstein AR, Gibson SB, Garcia LR, Meier P, Bhullar KS, Hubbard BP, Fiteh Y, Vliagoftis H, Goping IS, Brocks D, Hwang P, Velázquez-Martínez CA, Baksh S. Identification and Characterization of Novel Receptor-Interacting Serine/Threonine-Protein Kinase 2 Inhibitors Using Structural Similarity Analysis. J Pharmacol Exp Ther 2018; 365:354-367. [PMID: 29555876 DOI: 10.1124/jpet.117.247163] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2017] [Accepted: 02/26/2018] [Indexed: 12/16/2022] Open
Abstract
Receptor-interacting protein kinase 2 (RIP2 or RICK, herein referred to as RIPK2) is linked to the pathogen pathway that activates nuclear factor κ-light-chain-enhancer of activated B cells (NFκB) and autophagic activation. Using molecular modeling (docking) and chemoinformatics analyses, we used the RIPK2/ponatinib crystal structure and searched in chemical databases for small molecules exerting binding interactions similar to those exerted by ponatinib. The identified RIPK2 inhibitors potently inhibited the proliferation of cancer cells by > 70% and also inhibited NFκB activity. More importantly, in vivo inhibition of intestinal and lung inflammation rodent models suggests effectiveness to resolve inflammation with low toxicity to the animals. Thus, our identified RIPK2 inhibitor may offer possible therapeutic control of inflammation in diseases such as inflammatory bowel disease, asthma, cystic fibrosis, primary sclerosing cholangitis, and pancreatitis.
Collapse
Affiliation(s)
- Mohamed Salla
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Rodrigo Aguayo-Ortiz
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Gaddafi I Danmaliki
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Alaa Zare
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Ahmed Said
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Jack Moore
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Vrajeshkumar Pandya
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Robin Manaloor
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Sunny Fong
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Anna R Blankstein
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Spencer B Gibson
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Laura Ramos Garcia
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Pascal Meier
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Khushwant S Bhullar
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Basil P Hubbard
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Yahya Fiteh
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Harissios Vliagoftis
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Ing Swie Goping
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Dion Brocks
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Peter Hwang
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Carlos A Velázquez-Martínez
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| | - Shairaz Baksh
- Departments of Biochemistry (M.S., G.I.D., A.S., J.M., V.P., I.S.G., P.H., S.B.), Pediatrics (A.Z., R.M., S.F., S.B.), Pharmacology (K.S.B., B.P.H.), Oncology (S.B.) Medicine (Y.F., H.V., P.H.), and Faculty of Pharmacy and Pharmaceutical Sciences (R.A.-O., D.B., C.A.-V.M.), University of Alberta, Edmonton, Alberta, Canada; Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Mexico City, Mexico (R.A.-O.); Departments of Biochemistry and Medical Genetics and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada (A.R.B., S.B.G.); Breakthrough Breast Cancer Research Center Chester Beatty Laboratories, London, United Kingdom (L.R.G., P.M.); Cancer Research Institute of Northern Alberta, Edmonton, Alberta, Canada (S.B.); and Women and Children's Health Research Institute, Edmonton, Alberta, Canada (S.B.)
| |
Collapse
|
18
|
Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, Rupasinghe HPV. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer 2018; 17:48. [PMID: 29455673 PMCID: PMC5817855 DOI: 10.1186/s12943-018-0804-2] [Citation(s) in RCA: 658] [Impact Index Per Article: 109.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2017] [Accepted: 02/01/2018] [Indexed: 02/06/2023] Open
Abstract
The human genome encodes 538 protein kinases that transfer a γ-phosphate group from ATP to serine, threonine, or tyrosine residues. Many of these kinases are associated with human cancer initiation and progression. The recent development of small-molecule kinase inhibitors for the treatment of diverse types of cancer has proven successful in clinical therapy. Significantly, protein kinases are the second most targeted group of drug targets, after the G-protein-coupled receptors. Since the development of the first protein kinase inhibitor, in the early 1980s, 37 kinase inhibitors have received FDA approval for treatment of malignancies such as breast and lung cancer. Furthermore, about 150 kinase-targeted drugs are in clinical phase trials, and many kinase-specific inhibitors are in the preclinical stage of drug development. Nevertheless, many factors confound the clinical efficacy of these molecules. Specific tumor genetics, tumor microenvironment, drug resistance, and pharmacogenomics determine how useful a compound will be in the treatment of a given cancer. This review provides an overview of kinase-targeted drug discovery and development in relation to oncology and highlights the challenges and future potential for kinase-targeted cancer therapies.
Collapse
Affiliation(s)
- Khushwant S Bhullar
- Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Naiara Orrego Lagarón
- Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain
| | - Eileen M McGowan
- Chronic Disease Solutions Team, School of Life Science, University of Technology, New South Wales, Australia
| | - Indu Parmar
- Division of Product Development, Radient Technologies, Edmonton, AB, Canada
| | - Amitabh Jha
- Department of Chemistry, Acadia University, Wolfville, NS, Canada
| | - Basil P Hubbard
- Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - H P Vasantha Rupasinghe
- Department of Plant, Food, and Environmental Sciences, Faculty of Agriculture, Dalhousie University, Truro, NS, Canada.
- Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.
| |
Collapse
|
19
|
Li J, Bonkowski MS, Moniot S, Zhang D, Hubbard BP, Ling AJY, Rajman LA, Qin B, Lou Z, Gorbunova V, Aravind L, Steegborn C, Sinclair DA. A conserved NAD + binding pocket that regulates protein-protein interactions during aging. Science 2017; 355:1312-1317. [PMID: 28336669 DOI: 10.1126/science.aad8242] [Citation(s) in RCA: 117] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2015] [Revised: 08/15/2016] [Accepted: 02/24/2017] [Indexed: 12/18/2022]
Abstract
DNA repair is essential for life, yet its efficiency declines with age for reasons that are unclear. Numerous proteins possess Nudix homology domains (NHDs) that have no known function. We show that NHDs are NAD+ (oxidized form of nicotinamide adenine dinucleotide) binding domains that regulate protein-protein interactions. The binding of NAD+ to the NHD domain of DBC1 (deleted in breast cancer 1) prevents it from inhibiting PARP1 [poly(adenosine diphosphate-ribose) polymerase], a critical DNA repair protein. As mice age and NAD+ concentrations decline, DBC1 is increasingly bound to PARP1, causing DNA damage to accumulate, a process rapidly reversed by restoring the abundance of NAD+ Thus, NAD+ directly regulates protein-protein interactions, the modulation of which may protect against cancer, radiation, and aging.
Collapse
Affiliation(s)
- Jun Li
- Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA 02115, USA
| | - Michael S Bonkowski
- Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA 02115, USA
| | - Sébastien Moniot
- Department of Biochemistry, University of Bayreuth, 95440 Bayreuth, Germany
| | - Dapeng Zhang
- National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA
| | - Basil P Hubbard
- Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA 02115, USA
| | - Alvin J Y Ling
- Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA 02115, USA
| | - Luis A Rajman
- Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA 02115, USA
| | - Bo Qin
- Division of Oncology Research, Department of Oncology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
| | - Zhenkun Lou
- Division of Oncology Research, Department of Oncology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
| | - Vera Gorbunova
- Division of Biology, 434 Hutchinson Hall, River Campus, University of Rochester, Rochester, NY 14627, USA
| | - L Aravind
- National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA
| | - Clemens Steegborn
- Department of Biochemistry, University of Bayreuth, 95440 Bayreuth, Germany
| | - David A Sinclair
- Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA 02115, USA. .,Department of Pharmacology, School of Medical Sciences, The University of New South Wales, Sydney, New South Wales 2052, Australia
| |
Collapse
|
20
|
Abstract
The NAD(+)-dependent deacetylase SIRT1 plays key roles in numerous cellular processes including DNA repair, gene transcription, cell differentiation, and metabolism. Overexpression of SIRT1 protects against a number of age-related diseases including diabetes, cancer, and Alzheimer's disease. Moreover, overexpression of SIRT1 in the murine brain extends lifespan. A number of small-molecule sirtuin-activating compounds (STACs) that increase SIRT1 activity in vitro and in cells have been developed. While the mechanism for how these compounds act on SIRT1 was once controversial, it is becoming increasingly clear that they directly interact with SIRT1 and enhance its activity through an allosteric mechanism. Here, we present detailed chemical syntheses for four STACs, each from a distinct structural class. Also, we provide a general protocol for purifying active SIRT1 enzyme and outline two complementary enzymatic assays for characterizing the effects of STACs and similar compounds on SIRT1 activity.
Collapse
Affiliation(s)
- H Dai
- Sirtuin DPU, GlaxoSmithKline (GSK), Collegeville, PA, United States
| | - J L Ellis
- Sirtuin DPU, GlaxoSmithKline (GSK), Collegeville, PA, United States
| | - D A Sinclair
- Glenn Labs for the Biological Mechanisms of Aging, Harvard Medical School, Boston, MA, United States; The University of New South Wales, Sydney, NSW, Australia
| | - B P Hubbard
- University of Alberta, Edmonton, AB, Canada.
| |
Collapse
|
21
|
Hubbard BP, Badran AH, Zuris JA, Guilinger JP, Davis KM, Chen L, Tsai SQ, Sander JD, Joung JK, Liu DR. Continuous directed evolution of DNA-binding proteins to improve TALEN specificity. Nat Methods 2015; 12:939-42. [PMID: 26258293 PMCID: PMC4589463 DOI: 10.1038/nmeth.3515] [Citation(s) in RCA: 76] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2015] [Accepted: 06/26/2015] [Indexed: 11/09/2022]
Abstract
Nucleases containing programmable DNA-binding domains can alter the genomes of model organisms and have the potential to become human therapeutics. Here we present DNA-binding phage-assisted continuous evolution (DB-PACE) as a general approach for the laboratory evolution of DNA-binding activity and specificity. We used this system to generate transcription activator-like effectors nucleases (TALENs) with broadly improved DNA cleavage specificity, establishing DB-PACE as a versatile approach for improving the accuracy of genome-editing agents.
Collapse
Affiliation(s)
- Basil P Hubbard
- Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts, USA
| | - Ahmed H Badran
- Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts, USA
| | - John A Zuris
- Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts, USA
| | - John P Guilinger
- Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts, USA
| | - Kevin M Davis
- Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts, USA
| | - Liwei Chen
- Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts, USA
| | - Shengdar Q Tsai
- Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, Massachusetts, USA.,Center for Cancer Research, Massachusetts General Hospital, Charlestown, Massachusetts, USA.,Center for Computational and Integrative Biology, Massachusetts General Hospital, Charlestown, Massachusetts, USA.,Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA
| | - Jeffry D Sander
- Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, Massachusetts, USA.,Center for Cancer Research, Massachusetts General Hospital, Charlestown, Massachusetts, USA.,Center for Computational and Integrative Biology, Massachusetts General Hospital, Charlestown, Massachusetts, USA.,Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA
| | - J Keith Joung
- Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, Massachusetts, USA.,Center for Cancer Research, Massachusetts General Hospital, Charlestown, Massachusetts, USA.,Center for Computational and Integrative Biology, Massachusetts General Hospital, Charlestown, Massachusetts, USA.,Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA
| | - David R Liu
- Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts, USA.,Howard Hughes Medical Institute, Harvard University, Cambridge, Massachusetts, USA
| |
Collapse
|
22
|
Bhullar KS, Hubbard BP. Lifespan and healthspan extension by resveratrol. Biochim Biophys Acta Mol Basis Dis 2015; 1852:1209-18. [PMID: 25640851 DOI: 10.1016/j.bbadis.2015.01.012] [Citation(s) in RCA: 173] [Impact Index Per Article: 19.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2014] [Revised: 01/15/2015] [Accepted: 01/20/2015] [Indexed: 01/02/2023]
Abstract
A number of small molecules with the ability to extend the lifespan of multiple organisms have recently been discovered. Resveratrol, amongst the most prominent of these, has gained widespread attention due to its ability to extend the lifespan of yeast, worms, and flies, and its ability to protect against age-related diseases such as cancer, Alzheimer's, and diabetes in mammals. In this review, we discuss the origins and molecular targets of resveratrol and provide an overview of its effects on the lifespan of simple model organisms and mammals. We also examine the unique ability of resveratrol to extend the healthy years, or healthspan, of mammals and its potential to counteract the symptoms of age-related disease. Finally, we explore the many scientific, medical, and economic challenges faced when translating these findings to the clinic, and examine potential approaches for realizing the possibility of human lifespan extension. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.
Collapse
Affiliation(s)
- Khushwant S Bhullar
- Department of Pharmacology, University of Alberta, Edmonton, AB, T6G 2H7, Canada
| | - Basil P Hubbard
- Department of Pharmacology, University of Alberta, Edmonton, AB, T6G 2H7, Canada.
| |
Collapse
|
23
|
Hubbard BP, Loh C, Gomes AP, Li J, Lu Q, Doyle TL, Disch JS, Armour SM, Ellis JL, Vlasuk GP, Sinclair DA. Carboxamide SIRT1 inhibitors block DBC1 binding via an acetylation-independent mechanism. Cell Cycle 2014; 12:2233-40. [PMID: 23892437 DOI: 10.4161/cc.25268] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
SIRT1 is an NAD (+) -dependent deacetylase that counteracts multiple disease states associated with aging and may underlie some of the health benefits of calorie restriction. Understanding how SIRT1 is regulated in vivo could therefore lead to new strategies to treat age-related diseases. SIRT1 forms a stable complex with DBC1, an endogenous inhibitor. Little is known regarding the biochemical nature of SIRT1-DBC1 complex formation, how it is regulated and whether or not it is possible to block this interaction pharmacologically. In this study, we show that critical residues within the catalytic core of SIRT1 mediate binding to DBC1 via its N-terminal region, and that several carboxamide SIRT1 inhibitors, including EX-527, can completely block this interaction. We identify two acetylation sites on DBC1 that regulate its ability to bind SIRT1 and suppress its activity. Furthermore, we show that DBC1 itself is a substrate for SIRT1. Surprisingly, the effect of EX-527 on SIRT1-DBC1 binding is independent of DBC1 acetylation. Together, these data show that protein acetylation serves as an endogenous regulatory mechanism for SIRT1-DBC1 binding and illuminate a new path to developing small-molecule modulators of SIRT1.
Collapse
Affiliation(s)
- Basil P Hubbard
- Department of Genetics, Harvard Medical School, Boston, MA, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Gomes AP, Price NL, Ling AJY, Moslehi JJ, Montgomery MK, Rajman L, White JP, Teodoro JS, Wrann CD, Hubbard BP, Mercken EM, Palmeira CM, de Cabo R, Rolo AP, Turner N, Bell EL, Sinclair DA. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 2014; 155:1624-38. [PMID: 24360282 DOI: 10.1016/j.cell.2013.11.037] [Citation(s) in RCA: 989] [Impact Index Per Article: 98.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2012] [Revised: 10/25/2013] [Accepted: 11/21/2013] [Indexed: 11/25/2022]
Abstract
Ever since eukaryotes subsumed the bacterial ancestor of mitochondria, the nuclear and mitochondrial genomes have had to closely coordinate their activities, as each encode different subunits of the oxidative phosphorylation (OXPHOS) system. Mitochondrial dysfunction is a hallmark of aging, but its causes are debated. We show that, during aging, there is a specific loss of mitochondrial, but not nuclear, encoded OXPHOS subunits. We trace the cause to an alternate PGC-1α/β-independent pathway of nuclear-mitochondrial communication that is induced by a decline in nuclear NAD(+) and the accumulation of HIF-1α under normoxic conditions, with parallels to Warburg reprogramming. Deleting SIRT1 accelerates this process, whereas raising NAD(+) levels in old mice restores mitochondrial function to that of a young mouse in a SIRT1-dependent manner. Thus, a pseudohypoxic state that disrupts PGC-1α/β-independent nuclear-mitochondrial communication contributes to the decline in mitochondrial function with age, a process that is apparently reversible.
Collapse
Affiliation(s)
- Ana P Gomes
- Glenn Labs for the Biological Mechanisms of Aging, Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Center for Neurosciences and Cell Biology, 3004-517 Coimbra, Portugal; Department of Life Sciences, Faculty of Science and Technology, University of Coimbra, 3004-517 Coimbra, Portugal
| | - Nathan L Price
- Glenn Labs for the Biological Mechanisms of Aging, Department of Genetics, Harvard Medical School, Boston, MA 02115, USA
| | - Alvin J Y Ling
- Glenn Labs for the Biological Mechanisms of Aging, Department of Genetics, Harvard Medical School, Boston, MA 02115, USA
| | - Javid J Moslehi
- Department of Medical Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Magdalene K Montgomery
- Department of Pharmacology, School of Medical Sciences, The University of New South Wales, Sydney NSW 2052, Australia
| | - Luis Rajman
- Glenn Labs for the Biological Mechanisms of Aging, Department of Genetics, Harvard Medical School, Boston, MA 02115, USA
| | - James P White
- Dana-Farber Cancer Institute, Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
| | - João S Teodoro
- Center for Neurosciences and Cell Biology, 3004-517 Coimbra, Portugal; Department of Life Sciences, Faculty of Science and Technology, University of Coimbra, 3004-517 Coimbra, Portugal
| | - Christiane D Wrann
- Dana-Farber Cancer Institute, Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
| | - Basil P Hubbard
- Glenn Labs for the Biological Mechanisms of Aging, Department of Genetics, Harvard Medical School, Boston, MA 02115, USA
| | - Evi M Mercken
- Laboratory of Experimental Gerontology, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA
| | - Carlos M Palmeira
- Center for Neurosciences and Cell Biology, 3004-517 Coimbra, Portugal; Department of Life Sciences, Faculty of Science and Technology, University of Coimbra, 3004-517 Coimbra, Portugal
| | - Rafael de Cabo
- Laboratory of Experimental Gerontology, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA
| | - Anabela P Rolo
- Center for Neurosciences and Cell Biology, 3004-517 Coimbra, Portugal; Department of Biology, University of Aveiro, 3810-193 Aveiro, Portugal
| | - Nigel Turner
- Department of Pharmacology, School of Medical Sciences, The University of New South Wales, Sydney NSW 2052, Australia
| | - Eric L Bell
- Department of Biology, Massachusetts Institute of Technology, Paul F. Glenn Laboratory for the Science of Aging, Cambridge, MA 02139, USA
| | - David A Sinclair
- Glenn Labs for the Biological Mechanisms of Aging, Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Department of Pharmacology, School of Medical Sciences, The University of New South Wales, Sydney NSW 2052, Australia.
| |
Collapse
|
25
|
Hubbard BP, Sinclair DA. Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol Sci 2014; 35:146-54. [PMID: 24439680 DOI: 10.1016/j.tips.2013.12.004] [Citation(s) in RCA: 404] [Impact Index Per Article: 40.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2013] [Revised: 12/09/2013] [Accepted: 12/10/2013] [Indexed: 01/28/2023]
Abstract
Recent studies in mice have identified single molecules that can delay multiple diseases of aging and extend lifespan. In theory, such molecules could prevent dozens of diseases simultaneously, potentially extending healthy years of life. In this review, we discuss recent advances, controversies, opportunities, and challenges surrounding the development of SIRT1 activators, molecules with the potential to delay aging and age-related diseases. Sirtuins comprise a family of NAD⁺-dependent deacylases that are central to the body's response to diet and exercise. New studies indicate that both natural and synthetic sirtuin activating compounds (STACs) work via a common allosteric mechanism to stimulate sirtuin activity, thereby conferring broad health benefits in rodents, primates, and possibly humans. The fact that two-thirds of people in the USA who consume multiple dietary supplements consume resveratrol, a SIRT1 activator, underscores the importance of understanding the biochemical mechanism, physiological effects, and safety of STACs.
Collapse
Affiliation(s)
- Basil P Hubbard
- Department of Genetics, Harvard Medical School, Boston, MA 02115, USA
| | - David A Sinclair
- Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Department of Pharmacology, School of Medical Sciences, The University of New South Wales, Sydney, NSW 2052, Australia.
| |
Collapse
|
26
|
Minor RK, Baur JA, Gomes AP, Ward TM, Csiszar A, Mercken EM, Abdelmohsen K, Shin YK, Canto C, Scheibye-Knudsen M, Krawczyk M, Irusta PM, Martín-Montalvo A, Hubbard BP, Zhang Y, Lehrmann E, White AA, Price NL, Swindell WR, Pearson KJ, Becker KG, Bohr VA, Gorospe M, Egan JM, Talan MI, Auwerx J, Westphal CH, Ellis JL, Ungvari Z, Vlasuk GP, Elliott PJ, Sinclair DA, de Cabo R. Erratum: CORRIGENDUM: SRT1720 improves survival and healthspan of obese mice. Sci Rep 2013. [PMCID: PMC3546498 DOI: 10.1038/srep01131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, Riera TV, Lee JE, E SY, Lamming DW, Pentelute BL, Schuman ER, Stevens LA, Ling AJY, Armour SM, Michan S, Zhao H, Jiang Y, Sweitzer SM, Blum CA, Disch JS, Ng PY, Howitz KT, Rolo AP, Hamuro Y, Moss J, Perni RB, Ellis JL, Vlasuk GP, Sinclair DA. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013; 339:1216-9. [PMID: 23471411 DOI: 10.1126/science.1231097] [Citation(s) in RCA: 466] [Impact Index Per Article: 42.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
A molecule that treats multiple age-related diseases would have a major impact on global health and economics. The SIRT1 deacetylase has drawn attention in this regard as a target for drug design. Yet controversy exists around the mechanism of sirtuin-activating compounds (STACs). We found that specific hydrophobic motifs found in SIRT1 substrates such as PGC-1α and FOXO3a facilitate SIRT1 activation by STACs. A single amino acid in SIRT1, Glu(230), located in a structured N-terminal domain, was critical for activation by all previously reported STAC scaffolds and a new class of chemically distinct activators. In primary cells reconstituted with activation-defective SIRT1, the metabolic effects of STACs were blocked. Thus, SIRT1 can be directly activated through an allosteric mechanism common to chemically diverse STACs.
Collapse
Affiliation(s)
- Basil P Hubbard
- Department of Genetics, Harvard Medical School, Boston, MA 02115, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Biason-Lauber A, Böni-Schnetzler M, Hubbard BP, Bouzakri K, Brunner A, Cavelti-Weder C, Keller C, Meyer-Böni M, Meier DT, Brorsson C, Timper K, Leibowitz G, Patrignani A, Bruggmann R, Boily G, Zulewski H, Geier A, Cermak JM, Elliott P, Ellis JL, Westphal C, Knobel U, Eloranta JJ, Kerr-Conte J, Pattou F, Konrad D, Matter CM, Fontana A, Rogler G, Schlapbach R, Regairaz C, Carballido JM, Glaser B, McBurney MW, Pociot F, Sinclair DA, Donath MY. Identification of a SIRT1 mutation in a family with type 1 diabetes. Cell Metab 2013; 17:448-455. [PMID: 23473037 PMCID: PMC3746172 DOI: 10.1016/j.cmet.2013.02.001] [Citation(s) in RCA: 89] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/18/2012] [Revised: 12/30/2012] [Accepted: 02/07/2013] [Indexed: 02/07/2023]
Abstract
Type 1 diabetes is caused by autoimmune-mediated β cell destruction leading to insulin deficiency. The histone deacetylase SIRT1 plays an essential role in modulating several age-related diseases. Here we describe a family carrying a mutation in the SIRT1 gene, in which all five affected members developed an autoimmune disorder: four developed type 1 diabetes, and one developed ulcerative colitis. Initially, a 26-year-old man was diagnosed with the typical features of type 1 diabetes, including lean body mass, autoantibodies, T cell reactivity to β cell antigens, and a rapid dependence on insulin. Direct and exome sequencing identified the presence of a T-to-C exchange in exon 1 of SIRT1, corresponding to a leucine-to-proline mutation at residue 107. Expression of SIRT1-L107P in insulin-producing cells resulted in overproduction of nitric oxide, cytokines, and chemokines. These observations identify a role for SIRT1 in human autoimmunity and unveil a monogenic form of type 1 diabetes.
Collapse
Affiliation(s)
- Anna Biason-Lauber
- Department of Medicine, University of Fribourg, CH-1700 Fribourg, Switzerland
| | - Marianne Böni-Schnetzler
- Endocrinology, Diabetes, and Metabolism, and Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland
| | - Basil P. Hubbard
- Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging, Harvard Medical School, Boston, MA 02115, USA
| | - Karim Bouzakri
- Department of Genetic Medicine and Development, University of Geneva, University Medical Center, 1211 Geneva, Switzerland
| | - Andrea Brunner
- Endocrinology, Diabetes, and Metabolism, and Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland
| | - Claudia Cavelti-Weder
- Endocrinology, Diabetes, and Metabolism, and Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland
| | - Cornelia Keller
- Endocrinology, Diabetes, and Metabolism, and Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland
| | - Monika Meyer-Böni
- Department of Medicine, University of Fribourg, CH-1700 Fribourg, Switzerland
| | - Daniel T. Meier
- Endocrinology, Diabetes, and Metabolism, and Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland
| | - Caroline Brorsson
- Glostrup Research Institute, Glostrup University Hospital, 2600 Glostrup, Denmark
| | - Katharina Timper
- Endocrinology, Diabetes, and Metabolism, and Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland
| | - Gil Leibowitz
- Endocrinology and Metabolism Service, Department of Medicine, Hadassah Hebrew University Medical Center, 91120 Jerusalem, Israel
| | - Andrea Patrignani
- Functional Genomic Center Zurich, Federal Institute of Technology University of Zurich, 8057 Zurich, Switzerland
| | - Remy Bruggmann
- Functional Genomic Center Zurich, Federal Institute of Technology University of Zurich, 8057 Zurich, Switzerland
| | - Gino Boily
- University of Ottawa, Ottawa, ON K1H 8L6, Canada
| | - Henryk Zulewski
- Endocrinology, Diabetes, and Metabolism, and Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland
| | - Andreas Geier
- Gastroenterology and Hepatology Center of Integrative Human Physiology and University Hospital Zurich, 8091 Zurich, Switzerland
| | | | | | | | | | - Urs Knobel
- Endocrinology, Diabetes, and Metabolism, and Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland
| | - Jyrki J. Eloranta
- Department of Clinical Pharmacology and Toxicology Center of Integrative Human Physiology and University Hospital Zurich, 8091 Zurich, Switzerland
| | | | | | - Daniel Konrad
- University Children's Hospital, 8032 Zurich, Switzerland
| | - Christian M. Matter
- Department of Cardiology Center of Integrative Human Physiology and University Hospital Zurich, 8091 Zurich, Switzerland
| | - Adriano Fontana
- Institute of Experimental Immunology University of Zurich, 8057 Zurich, Switzerland
| | - Gerhard Rogler
- Gastroenterology and Hepatology Center of Integrative Human Physiology and University Hospital Zurich, 8091 Zurich, Switzerland
| | - Ralph Schlapbach
- Functional Genomic Center Zurich, Federal Institute of Technology University of Zurich, 8057 Zurich, Switzerland
| | - Camille Regairaz
- Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland
| | | | - Benjamin Glaser
- Endocrinology and Metabolism Service, Department of Medicine, Hadassah Hebrew University Medical Center, 91120 Jerusalem, Israel
| | | | - Flemming Pociot
- Glostrup Research Institute, Glostrup University Hospital, 2600 Glostrup, Denmark
| | - David A. Sinclair
- Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging, Harvard Medical School, Boston, MA 02115, USA
| | - Marc Y. Donath
- Endocrinology, Diabetes, and Metabolism, and Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland
| |
Collapse
|
29
|
Rascón B, Hubbard BP, Sinclair DA, Amdam GV. The lifespan extension effects of resveratrol are conserved in the honey bee and may be driven by a mechanism related to caloric restriction. Aging (Albany NY) 2012; 4:499-508. [PMID: 22868943 PMCID: PMC3433935 DOI: 10.18632/aging.100474] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Our interest in healthy aging and in evolutionarily conserved mechanisms of lifespan extension prompted us to investigate whether features of age-related decline in the honey bee could be attenuated with resveratrol. Resveratrol is regarded as a caloric restriction mimetic known to extend lifespan in some but not all model species. The current, prevailing view is that resveratrol works largely by activating signaling pathways. It has also been suggested that resveratrol may act as an antioxidant and confer protection against nervous system impairment and oxidative stress. To test whether honey bee lifespan, learning performance, and food perception could be altered by resveratrol, we supplemented the diets of honey bees and measured lifespan, olfactory learning, and gustatory responsiveness to sucrose. Furthermore, to test the effects of resveratrol under metabolic challenge, we used hyperoxic environments to generate oxidative stress. Under normal oxygen conditions, two resveratrol treatments-30 and 130 μM-lengthened average lifespan in wild-type honey bees by 38% and 33%, respectively. Both resveratrol treatments also lengthened maximum and median lifespan. In contrast, hyperoxic stress abolished the resveratrol life-extension response. Furthermore, resveratrol did not affect learning performance, but did alter gustation. Honey bees that were not fed resveratrol exhibited greater responsiveness to sugar, while those supplemented with resveratrol were less responsive to sugar. We also discovered that individuals fed a high dose of resveratrol-compared to controls-ingested fewer quantities of food under ad libitum feeding conditions.
Collapse
Affiliation(s)
- Brenda Rascón
- Department of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway.
| | | | | | | |
Collapse
|
30
|
Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JS, Hubbard BP, Varela AT, Davis JG, Varamini B, Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, de Cabo R, Baur JA, Sinclair DA. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 2012; 15:675-90. [PMID: 22560220 PMCID: PMC3545644 DOI: 10.1016/j.cmet.2012.04.003] [Citation(s) in RCA: 1107] [Impact Index Per Article: 92.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/11/2011] [Revised: 02/14/2012] [Accepted: 04/06/2012] [Indexed: 02/06/2023]
Abstract
Resveratrol induces mitochondrial biogenesis and protects against metabolic decline, but whether SIRT1 mediates these benefits is the subject of debate. To circumvent the developmental defects of germline SIRT1 knockouts, we have developed an inducible system that permits whole-body deletion of SIRT1 in adult mice. Mice treated with a moderate dose of resveratrol showed increased mitochondrial biogenesis and function, AMPK activation, and increased NAD(+) levels in skeletal muscle, whereas SIRT1 knockouts displayed none of these benefits. A mouse overexpressing SIRT1 mimicked these effects. A high dose of resveratrol activated AMPK in a SIRT1-independent manner, demonstrating that resveratrol dosage is a critical factor. Importantly, at both doses of resveratrol no improvements in mitochondrial function were observed in animals lacking SIRT1. Together these data indicate that SIRT1 plays an essential role in the ability of moderate doses of resveratrol to stimulate AMPK and improve mitochondrial function both in vitro and in vivo.
Collapse
Affiliation(s)
- Nathan L. Price
- Glenn Labs for the Biological Mechanisms of Aging, Harvard Medical School, Boston, MA, 02115
| | - Ana P. Gomes
- Glenn Labs for the Biological Mechanisms of Aging, Harvard Medical School, Boston, MA, 02115
- Center for Neurosciences and Cell Biology, 3004-517 Coimbra, Portugal
| | - Alvin J.Y. Ling
- Glenn Labs for the Biological Mechanisms of Aging, Harvard Medical School, Boston, MA, 02115
| | - Filipe V. Duarte
- Center for Neurosciences and Cell Biology, 3004-517 Coimbra, Portugal
| | - Alejandro Martin-Montalvo
- Laboratory of Experimental Gerontology, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA
| | - Brian J. North
- Glenn Labs for the Biological Mechanisms of Aging, Harvard Medical School, Boston, MA, 02115
| | - Beamon Agarwal
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104
| | - Lan Ye
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104
| | - Giorgio Ramadori
- Department of Internal Medicine, Division of Hypothalamic Research, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Joao S. Teodoro
- Center for Neurosciences and Cell Biology, 3004-517 Coimbra, Portugal
| | - Basil P. Hubbard
- Glenn Labs for the Biological Mechanisms of Aging, Harvard Medical School, Boston, MA, 02115
| | - Ana T. Varela
- Center for Neurosciences and Cell Biology, 3004-517 Coimbra, Portugal
| | - James G. Davis
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104
| | - Behzad Varamini
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104
| | - Angela Hafner
- Glenn Labs for the Biological Mechanisms of Aging, Harvard Medical School, Boston, MA, 02115
| | - Ruin Moaddel
- Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA
| | - Anabela P. Rolo
- Center for Neurosciences and Cell Biology, 3004-517 Coimbra, Portugal
- Department of Biology, University of Aveiro, 3810-193, Aveiro Portugal
| | - Roberto Coppari
- Department of Internal Medicine, Division of Hypothalamic Research, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
- Dipartimento di Medicina Sperimentale e Clinica, Universita’ Politecnica delle Marche, Ancona 60020, Italy
| | - Carlos M. Palmeira
- Center for Neurosciences and Cell Biology, 3004-517 Coimbra, Portugal
- Department of Life Sciences, Faculty of Science and Technology, University of Coimbra, 3004-517 Coimbra, Portugal
| | - Rafael de Cabo
- Laboratory of Experimental Gerontology, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA
| | - Joseph A. Baur
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104
| | - David A. Sinclair
- Glenn Labs for the Biological Mechanisms of Aging, Harvard Medical School, Boston, MA, 02115
- Corresponding author: David A. Sinclair ()
| |
Collapse
|
31
|
Han J, Hubbard BP, Lee J, Montagna C, Lee HW, Sinclair DA, Suh Y. Analysis of 41 cancer cell lines reveals excessive allelic loss and novel mutations in the SIRT1 gene. Cell Cycle 2012; 12:263-70. [PMID: 23255128 DOI: 10.4161/cc.23056] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
SIRT1 is an evolutionarily conserved protein deacetylase that modulates stress response, cellular metabolism and aging in model organisms. While SIRT1 exerts beneficial effects in protecting against age-related diseases, the role of SIRT1 in cancer has been controversial. SIRT1 promotes cell survival by deacetylating, and thereby negatively regulating the activity of important tumor suppressors such as p53. In this regard, SIRT1 has been considered to be a potential oncogene, and SIRT1 inhibitors have been studied for possible anticancer therapeutic effects. In contrast, it has been shown that SIRT1 deficiency leads to increased genomic instability and tumorigenesis, and that overexpression of SIRT1 attenuates cancer formation in mice, suggesting it may also act as a tumor suppressor. Based on this evidence, SIRT1-activating molecules could act as candidate chemotherapeutic drugs. In order to gain insight into the role of SIRT1 in cancer, we performed a comprehensive resequencing analysis of the SIRT1 gene in 41 tumor cell lines and found an unusually excessive homozygosity, which was confirmed to be allelic loss by microsatellite analysis. Furthermore, we found two novel SIRT1 mutations (D739Y and R65_A72del) in addition to the known, rare non-synonymous variation resulting in I731V. In vitro assays using purified SIRT1 protein showed that these mutations do not alter SIRT1 deacetylase activity or telomerase activity, which was shown to be regulated by SIRT1. We conclude that allelic loss or mutations in the SIRT1 gene occur prevalently during tumorigenesis, supporting the assertion that SIRT1 may serve as a tumor suppressor.
Collapse
Affiliation(s)
- Jeehae Han
- Department of Genetics, Albert Einstein College of Medicine, Bronx, NY, USA
| | | | | | | | | | | | | |
Collapse
|
32
|
Gomes AP, Duarte FV, Nunes P, Hubbard BP, Teodoro JS, Varela AT, Jones JG, Sinclair DA, Palmeira CM, Rolo AP. Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. Biochim Biophys Acta Mol Basis Dis 2011; 1822:185-95. [PMID: 22027215 DOI: 10.1016/j.bbadis.2011.10.008] [Citation(s) in RCA: 111] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2011] [Revised: 10/07/2011] [Accepted: 10/07/2011] [Indexed: 11/25/2022]
Abstract
Berberine (BBR) has recently been shown to improve insulin sensitivity in rodent models of insulin resistance. Although this effect was explained partly through an observed activation of AMP-activated protein kinase (AMPK), the upstream and downstream mediators of this phenotype were not explored. Here, we show that BBR supplementation reverts mitochondrial dysfunction induced by High Fat Diet (HFD) and hyperglycemia in skeletal muscle, in part due to an increase in mitochondrial biogenesis. Furthermore, we observe that the prevention of mitochondrial dysfunction by BBR, the increase in mitochondrial biogenesis, as well as BBR-induced AMPK activation, are blocked in cells in which SIRT1 has been knocked-down. Taken together, these data reveal an important role for SIRT1 and mitochondrial biogenesis in the preventive effects of BBR on diet-induced insulin resistance.
Collapse
Affiliation(s)
- Ana P Gomes
- Center for Neurosciences and Cell Biology, Department of Life Sciences, University of Coimbra 3004-517 Coimbra, Portugal
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Bernier M, Paul RK, Martin-Montalvo A, Scheibye-Knudsen M, Song S, He HJ, Armour SM, Hubbard BP, Bohr VA, Wang L, Zong Y, Sinclair DA, de Cabo R. Negative regulation of STAT3 protein-mediated cellular respiration by SIRT1 protein. J Biol Chem 2011; 286:19270-9. [PMID: 21467030 DOI: 10.1074/jbc.m110.200311] [Citation(s) in RCA: 103] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
In mammals, the transcriptional activity of signal transducer and activator of transcription 3 (STAT3) is regulated by the deacetylase SIRT1. However, whether the newly described nongenomic actions of STAT3 toward mitochondrial oxidative phosphorylation are dependent on SIRT1 is unclear. In this study, Sirt1 gene knock-out murine embryonic fibroblast (MEF) cells were used to delineate the role of SIRT1 in the regulation of STAT3 mitochondrial function. Here, we show that STAT3 mRNA and protein levels and the accumulation of serine-phosphorylated STAT3 in mitochondria were increased significantly in Sirt1-KO cells as compared with wild-type MEFs. Various mitochondrial bioenergetic parameters, such as the oxygen consumption rate in cell cultures, enzyme activities of the electron transport chain complexes in isolated mitochondria, and production of ATP and lactate, indicated that Sirt1-KO cells exhibited higher mitochondrial respiration as compared with wild-type MEFs. Two independent approaches, including ectopic expression of SIRT1 and siRNA-mediated knockdown of STAT3, led to reduction in intracellular ATP levels and increased lactate production in Sirt1-KO cells that were approaching those of wild-type controls. Comparison of profiles of phospho-antibody array data indicated that the deletion of SirT1 was accompanied by constitutive activation of the pro-inflammatory NF-κB pathway, which is key for STAT3 induction and increased cellular respiration in Sirt1-KO cells. Thus, SIRT1 appears to be a functional regulator of NF-κB-dependent STAT3 expression that induces mitochondrial biogenesis. These results have implications for understanding the interplay between STAT3 and SIRT1 in pro-inflammatory conditions.
Collapse
Affiliation(s)
- Michel Bernier
- Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Yang Y, Hubbard BP, Sinclair DA, Tong Q. Characterization of murine SIRT3 transcript variants and corresponding protein products. J Cell Biochem 2011; 111:1051-8. [PMID: 20677216 DOI: 10.1002/jcb.22795] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
SIRT3 is one of the seven mammalian sirtuin homologs of the yeast SIR2 gene. SIRT3 possesses NAD(+)-dependent protein deacetylase activity. Recent studies indicate that the murine SIRT3 gene expresses different transcript variants, resulting in three possible SIRT3 protein isoforms with various lengths at the N-terminus: M1 (aa 1-334), M2 (aa 15-334), and M3 (aa 78-334). The transcript variants 1 and 3 can only produce M3 protein, while M1 and M2 proteins are translationally initiated from different in-frame ATG sites in transcript 2. Here we report that three transcript variants of the mouse SIRT3 gene are broadly expressed in various mouse tissues. By expressing these SIRT3 isoforms in HEK293 cells through transient transfection, we confirmed recent reports that two longer murine SIRT3 proteins (M1 and M2) are targeted to mitochondria with higher efficiency than the shorter M3 isoform. Additionally, the M1 and M2 proteins are processed into a mature form. Using Edman degradation we identify Ile38 (majority) or Val42 as the N-terminal amino acid of the mature M1 isoform, and Met78 or Val79 as the N-terminal amino acid of the M3 isoform. Interestingly, we found that even upon mutation of the M2 ATG site in the M1 cDNA, a processed mature protein could still be produced. In terms of deacetylase activity, we found that although only the mature protein derived from M1 or M2 proteins were active against acetylated peptide substrates, all three forms had equal deacetylase activity towards a full-length native protein substrate, acetyl CoA synthetase 2.
Collapse
Affiliation(s)
- Yongjie Yang
- USDA/ARS Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
| | | | | | | |
Collapse
|
35
|
Dai H, Kustigian L, Carney D, Case A, Considine T, Hubbard BP, Perni RB, Riera TV, Szczepankiewicz B, Vlasuk GP, Stein RL. SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. J Biol Chem 2010; 285:32695-32703. [PMID: 20702418 PMCID: PMC2963390 DOI: 10.1074/jbc.m110.133892] [Citation(s) in RCA: 181] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
SIRT1 is a protein deacetylase that has emerged as a therapeutic target for the development of activators to treat diseases of aging. SIRT1-activating compounds (STACs) have been developed that produce biological effects consistent with direct SIRT1 activation. At the molecular level, the mechanism by which STACs activate SIRT1 remains elusive. In the studies reported herein, the mechanism of SIRT1 activation is examined using representative compounds chosen from a collection of STACs. These studies reveal that activation of SIRT1 by STACs is strongly dependent on structural features of the peptide substrate. Significantly, and in contrast to studies reporting that peptides must bear a fluorophore for their deacetylation to be accelerated, we find that some STACs can accelerate the SIRT1-catalyzed deacetylation of specific unlabeled peptides composed only of natural amino acids. These results, together with others of this study, are at odds with a recent claim that complex formation between STACs and fluorophore-labeled peptides plays a role in the activation of SIRT1 (Pacholec, M., Chrunyk, B., Cunningham, D., Flynn, D., Griffith, D., Griffor, M., Loulakis, P., Pabst, B., Qiu, X., Stockman, B., Thanabal, V., Varghese, A., Ward, J., Withka, J., and Ahn, K. (2010) J. Biol. Chem. 285, 8340-8351). Rather, the data suggest that STACs interact directly with SIRT1 and activate SIRT1-catalyzed deacetylation through an allosteric mechanism.
Collapse
Affiliation(s)
- Han Dai
- From Sirtris, a GSK Company, Cambridge, Massachusetts 02139
| | | | - David Carney
- From Sirtris, a GSK Company, Cambridge, Massachusetts 02139
| | - April Case
- From Sirtris, a GSK Company, Cambridge, Massachusetts 02139
| | | | - Basil P Hubbard
- Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115
| | - Robert B Perni
- From Sirtris, a GSK Company, Cambridge, Massachusetts 02139
| | - Thomas V Riera
- From Sirtris, a GSK Company, Cambridge, Massachusetts 02139
| | | | | | - Ross L Stein
- From Sirtris, a GSK Company, Cambridge, Massachusetts 02139.
| |
Collapse
|